| 1.595 -0.125 (-7.27%) | 08-17 15:44 | |||||||||||||
|
|
| Short term | ||||
| Mid term | |
|||
| Targets | 6-month : | 2.1 |
1-year : | 2.45 |
| Resists | First : | 1.79 |
Second : | 2.1 |
| Pivot price | 1.26 |
|||
| Supports | First : | 1.23 |
Second : | 0.87 |
| MAs | MA(5) : | 1.55 |
MA(20) : | 1.2 |
| MA(100) : | 1.01 |
MA(250) : | 0.95 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 85.2 |
D(3) : | 90.1 |
| RSI | RSI(14): 65.6 |
|||
| 52-week | High : | 1.79 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MYO ] has closed below upper band by 19.7%. Bollinger Bands are 199.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.77 - 1.77 | 1.77 - 1.78 |
| Low: | 1.42 - 1.43 | 1.43 - 1.44 |
| Close: | 1.71 - 1.72 | 1.72 - 1.73 |
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Wed, 12 Aug 2026
Myomo (MYO): Rosalind Master Fund reports 9.18% stake and warrant blocker - Stock Titan
Sun, 09 Aug 2026
Myomo Q2 Earnings Call Highlights - TradingView
Wed, 05 Aug 2026
Is Myomo Inc (MYO) a Hidden Gem? Q2 Earnings Show Revenue of $11 - GuruFocus
Wed, 05 Aug 2026
Myomo Reports Second Quarter 2026 Financial and Operating Results - Business Wire
Wed, 05 Aug 2026
Myomo Inc (MYO) (Q2 2026) Earnings Call Highlights: Record Orders and Margin Expansion Drive Strong Quarter - GuruFocus
Wed, 05 Aug 2026
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |